Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy‐based virtual screening and machine learning evaluation
Xi Chen(Zhejiang Cancer Hospital), Tao Lei(Zhejiang Cancer Hospital), Haiyan Yang(Chinese Academy of Sciences), Roufen Chen(Zhejiang Lab), Lei Xu(Chinese Academy of Sciences), Jingyi Zhao(Zhejiang University), Shuangshuang Geng(Zhejiang University), Zhichao Pan(Zhejiang Lab), Yu Guo(Zhejiang University), Jialiang Lu(Zhejiang University), Xinjun He(Zhejiang Lab), Qingnan Zhang(Zhejiang Lab), Xinglong Chi(State Key Laboratory of Natural Medicine), Liteng Shen(Zhejiang Lab), Zheyuan Shen(Second Affiliated Hospital of Zhejiang University)
Cited by 2
Related Papers
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
ADCdb: the database of antibody–drug conjugates
|Nucleic Acids Research|2023|69
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
|The Lancet Oncology|2023|55
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
|Journal of Hematology & Oncology|2020|50